Mizuho Reiterates “$24.00” Price Target for Akebia Therapeutics (AKBA)
A number of other research firms have also weighed in on AKBA. ValuEngine lowered Akebia Therapeutics from a hold rating to a sell rating in a research report on Friday, December 1st. Zacks Investment Research raised Akebia Therapeutics from a hold rating to a buy rating and set a $17.00 price objective on the stock in a research report on Monday, November 13th. BTIG Research assumed coverage on Akebia Therapeutics in a research report on Thursday, December 7th. They set a buy rating and a $30.00 price objective on the stock. Piper Jaffray Companies assumed coverage on Akebia Therapeutics in a research report on Monday, December 18th. They set an overweight rating and a $26.00 price objective on the stock. Finally, BidaskClub lowered Akebia Therapeutics from a hold rating to a sell rating in a research report on Thursday, February 22nd. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and eight have given a buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus price target of $22.20.
Shares of Akebia Therapeutics (NASDAQ AKBA) opened at $14.08 on Wednesday. Akebia Therapeutics has a 12-month low of $8.69 and a 12-month high of $20.25.
ILLEGAL ACTIVITY NOTICE: This piece was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another website, it was illegally stolen and republished in violation of international trademark & copyright laws. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2018/03/11/mizuho-reiterates-24-00-price-target-for-akebia-therapeutics-akba.html.
About Akebia Therapeutics
Akebia Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company’s lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD).
Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.